My research is focused on diagnostic/therapeutic applications of monoclonal antibodies (mAbs). We develop mAbs to probe biosynthesis of mucin-type O-glycosylation and truncated cancer O-glycans. Our mAbs directed to mucins with truncated O-glycans have cancer-specific reactivity. One mAb designated 5E5 is directed to a cancer-specific epitope on mucin-1, and this is now in a phase 1 clinical trial (CAR-T) at UPENN/Tmunity with collaborators. A novel cell-based mucin display platform is used to explore immunogenicity of human cancer mucins for vaccine developments and to generate novel cancer-specific mAbs. One of these novel mAbs is currently under preclinical evaluation by a company.